ERBB2 and cancer: Furthermore, the advent of trastuzumab and the human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate trastuzumab deruxtecan for HER2-positive G/GEJ cancer, has improved the prognosis of HER2-positive G/GEJ cancer11,12.